Quoin Pharmaceuticals, Ltd. (QNRX)
Data as of , from SEC Form 4 filings.
See up to 3 months of QNRX. The 7-day demo opens the 1M and 3M ranges and puts QNRX on your watchlist.
Start 7-day demoLatest QNRX insider trades
About Quoin Pharmaceuticals, Ltd. (QNRX)
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
- KFAR SABA
- 6
- 2021
- XNAS
QNRX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 8 | 86,055 | $280K |
| Grant or award | 2 | 65,886 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
QNRX insider transactions (Form 4)
4534 Form 4 filings on record, the earliest from Dec 10, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Denise P. Carter - Officer | Open-market purchase | ADSs | 20,490 | $4.88 | $100K | |
| Denise P. Carter - Officer | Open-market purchase | Ordinary Warrants (Right to Buy) | 10,245 | - footnote F2 | - | |
| ||||||
| Michael Myers - Officer | Open-market purchase | ADSs | 20,490 | $4.88 | $100K | |
| Michael Myers - Officer | Open-market purchase | Ordinary Warrants (Right to Buy) | 10,245 | - footnote F2 | - | |
| ||||||
| Sally Bridget Lawlor - Officer | Open-market purchase | ADSs | 10,244 | $4.88 | $50K | |
| Sally Bridget Lawlor - Officer | Open-market purchase | Ordinary Warrants (Right to Buy) | 5,122 | - footnote F2 | - | |
| ||||||
| Anthony James Culverwell - Director | Open-market purchase | ADSs | 6,146 | $4.88 | $30K | |
| Anthony James Culverwell - Director | Open-market purchase | Ordinary Warrants (Right to Buy) | 3,073 | - footnote F2 | - | |
| ||||||
| Dennis Langer - Director | Grant or award | ADSs | 34,534 | $5.15 | $178K | |
| Anthony James Culverwell - Director | Grant or award | ADSs | 31,352 | $5.15 | $161K | |
| Sally Bridget Lawlor - Officer | Grant or award | Share Option (Right to Buy) | 85,250 footnote F1 | $0.00 | - | |
| ||||||
| Joseph Patrick Cooper - Director | Grant or award | Share Option (Right to Buy) | 8,141 footnote F1 | $0.00 | - | |
| ||||||
| Anthony James Culverwell - Director | Grant or award | Share Option (Right to Buy) | 21,709 footnote F1 | $0.00 | - | |
| ||||||
| Michael Myers - Officer | Grant or award | Share Option (Right to Buy) | 318,750 footnote F1 | $0.00 | - | |
| ||||||
| Denise P. Carter - Officer | Grant or award | Share Option (Right to Buy) | 318,750 footnote F1 | $0.00 | - | |
| ||||||
| Dennis Langer - Director | Grant or award | Share Option (Right to Buy) | 21,709 footnote F1 | $0.00 | - | |
| ||||||
| Michael T. Sember - Director | Grant or award | Share Option (Right to Buy) | 8,141 footnote F1 | $0.00 | - | |
| ||||||
| Natalie Ee Mun Leong - Director | Grant or award | Share Option (Right to Buy) | 12,211 footnote F1 | $0.00 | - | |
| ||||||
| Sally Bridget Lawlor - Officer | Grant or award | Share Option (Right to Buy) | 10,330 footnote F1 | $0.00 | - | |
| ||||||
| Dennis Langer - Director | Open-market purchase | ADSs | 15,152 | $8.49 | $129K | |
| Dennis Langer - Director | Open-market purchase | Series H Warrants (Right to Buy) | 15,152 | - footnote F2 | - | |
| Dennis Langer - Director | Open-market purchase | Series I Warrants (Right to Buy) | 15,152 | - footnote F2 | - | |
| Dennis Langer - Director | Open-market purchase | Series J Warrants (Right to Buy) | 15,152 | - footnote F2 | - | |
| Dennis Langer - Director | Open-market purchase | Series K Warrants (Right to Buy) | 15,152 | - footnote F2 | - | |
| ||||||
| Natalie Ee Mun Leong - Director | Grant or award | Share Option (Right to Buy) | 4,105 | $0.00 | - | |
| Anthony James Culverwell - Director | Grant or award | Share Option (Right to Buy) | 13,682 | $0.00 | - | |
| Dennis Langer - Director | Grant or award | Share Option (Right to Buy) | 13,682 | $0.00 | - | |
| Dennis Langer - Director | Grant or award | Share Option (Right to Buy) | 7,760 | $0.00 | - | |
| Michael T. Sember - Director | Grant or award | Share Option (Right to Buy) | 7,760 | $0.00 | - | |
| Denise P. Carter - Officer | Open-market purchase | Ordinary Shares | 555,556 | $15.75 | $250K | |
| Denise P. Carter - Officer | Open-market purchase | Series F Warrants (right to buy) | 555,556 | - | - | |
| Denise P. Carter - Officer | Open-market purchase | Series G Warrants (right to buy) | 555,556 | - | - | |
| Michael Myers - Officer | Open-market purchase | Ordinary Shares | 555,556 | $15.75 | $250K | |
| Michael Myers - Officer | Open-market purchase | Series F Warrants (right to buy) | 555,556 | - | - | |
| Michael Myers - Officer | Open-market purchase | Series G Warrants (right to buy) | 555,556 | - | - | |
| Gordon Dunn - Officer | Open-market purchase | Ordinary Shares | 122,221 | $15.75 | $55K | |
| Gordon Dunn - Officer | Open-market purchase | Series F Warrants (right to buy) | 122,221 | - | - | |
| Gordon Dunn - Officer | Open-market purchase | Series G Warrants (right to buy) | 122,221 | - | - | |
| Anthony James Culverwell - Director | Open-market purchase | Ordinary Shares | 100,000 | $15.75 | $45K | |
| Anthony James Culverwell - Director | Open-market purchase | Series F Warrants (right to buy) | 100,000 | - | - | |
| Anthony James Culverwell - Director | Open-market purchase | Series G Warrants (right to buy) | 100,000 | - | - | |
| Gordon Dunn - Officer | Grant or award | Share Option (Right to Buy) | 338,994 | $0.00 | - | |
| Anthony James Culverwell - Director | Grant or award | Share Option (Right to Buy) | 50,714 | $0.00 | - | |
| Denise P. Carter - Officer | Grant or award | Share Option (Right to Buy) | 536,609 | $0.00 | - | |
| Michael Myers - Officer | Grant or award | Share Option (Right to Buy) | 536,603 | $0.00 | - | |
Item 7.01, 8.01, 9.01
Item 7.01, 8.01, 9.01
Item 7.01, 8.01, 9.01
Item 1.01, 3.02, 7.01, 8.01, 9.01
QNRX insider trading FAQ
What is the latest insider trade for QNRX?
Quoin Pharmaceuticals, Ltd. (QNRX) had 6 insider filings in the last 90 days, with the most recent on 2026-09-02. The full record for QNRX runs to 34 Form 4 filings, the earliest from 2024-12-10. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying QNRX stock?
8 insider purchases of QNRX were filed in the last 90 days, totaling $280K.
How many insiders are selling QNRX stock?
No insider sales of QNRX were filed in the last 90 days.
Where can I see QNRX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects QNRX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Denise P. Carter view on EDGAR
- - Michael Myers view on EDGAR
- - Sally Bridget Lawlor view on EDGAR
- - Anthony James Culverwell view on EDGAR
- - Dennis Langer view on EDGAR
- - Anthony James Culverwell view on EDGAR
- - Stonepine Capital Management, LLC view on EDGAR
- - Sally Bridget Lawlor view on EDGAR
- - Joseph Patrick Cooper view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Insider activity in Health Care
- Where QNRX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow QNRX with a 7-day demo
- QNRX on your watchlist
- Every QNRX Form 4 filing on record
- Up to 3 months of QNRX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
